AstraZeneca (LON:AZN) has sold its site in West Chester, Ohio, to National Resilience, a San Diego–headquartered biomanufacturing company.
Resilience has agreed to maintain the site’s operations and assets while retaining its employees, including executives. The company will also continue investing in the site’s workforce and facility.
Privately-held National Resilience also has separately announced that it had reached a long-term biomanufacturing partnership supporting AstraZeneca’s portfolio.
That deal will give AstraZeneca access to Resilience’s end-to-end manufacturing services. In addition, Resilience agreed to purchase the West Chester facility and to manufacture several AstraZeneca drugs at the site as part of a multi-year supply agreement.
Resilience believes the West Cheser site will become its “global center of excellence for commercial drug product manufacturing,” noted Rahul Singhvi, Resilience CEO, …